Comments
Zydus Hospira Oncology Pvt Ltd, a 50:50 joint venture company between Zydus Cadila and Hospira Inc, US (now part of Pfizer Group), has received an establishment inspection report (EIR) from the USFDA. The US authority has concluded that the inspection is closed, stating that the inspection classification of this facility is ‘Voluntary Action Indicated’. The manufacturing plant had conducted the USFDA audit from April 5 to 12. Shares of Cadila Healthcare slipped 1.3 per cent at ₹366.70 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.